Exosens Stock Surpasses +108% in One Year, Targeting Key Resistance at €72.90
Exosens stock is trading at €66.55 this Tuesday mid-session, up 2.07% from the previous day's close. This increase extends a remarkable trend, with a gain of over 12% in the past seven days and an annual performance now exceeding 108%.
This Tuesday, Exosens stock is significantly above its 50-day moving average, which is at €60.46, and even more so above its 200-day moving average, which stands at €48.26. This increasing gap indicates a strong underlying bullish movement that has accelerated in recent weeks, with the stock price increasing by 25.8% over three months. The RSI, a momentum indicator, is at 54: a neutral level that signals neither overbuying nor exhaustion of the movement, leaving room before reaching an overbought zone. The stock is currently fluctuating between the Bollinger bands, with the upper bound at €74.32 and the lower bound at €56.31. The identified resistance level at €72.90 is the next technical threshold to watch, while the major support is positioned at €55.60. The monthly volatility remains contained at 13.48%, suggesting a relatively steady progression of the stock in the recent period.
Upcoming Catalysts for Exosens
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The next identified catalyst for Exosens is the publication of its first quarter 2026 results, scheduled for April 27. This event could be a crucial test for the stock, whose valuation has more than doubled in a year. The general meeting is scheduled for May 22, followed by the semi-annual results expected on July 28. In a generally buoyant Parisian market this Tuesday, with the CAC 40 up 1.33% at 8,068 points during the session, Exosens is moving in the same direction as the French index. However, disparities are noted among European technology stocks: ASML is down 3.03% while Schneider Electric is up 1.19%. The negative beta of the stock (?0.14) indicates a very low correlation with the overall market, suggesting that Exosens' dynamics are primarily driven by company-specific factors rather than general market movements.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.